Skip to content
Screener

Nektar Therapeutics NKTR Financing Cash Flow

Financing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$1.48B+44.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$223.93M+22,903%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$411.17M+66,004%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$283.27M
CTO
Citius Oncology, Inc.CTOR
$15.13M+299%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.48B+539%
Enterprise value$2.56B+435%
P/S44.6×+39.4×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-212596
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from underwritten offering, net of underwriting discounts of $27,600432,400
Proceeds from at-the-market offering, net of commissions of $2,88093,119
Payments of offering costs associated with issuance of common stock and pre-funded warrants(25)
Net cash provided by financing activities529,5497
Effect of foreign exchange rates on cash and cash equivalents-(1)
Net increase (decrease) in cash and cash equivalents134,462(5,358)
Cash and cash equivalents at beginning of period15,11644,252
Cash and cash equivalents at end of period$149,578$38,894

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's financing cash flow?
Nektar Therapeutics (NKTR) reported financing cash flow of $529.55M in Q1 2026.
How has Nektar Therapeutics's financing cash flow changed year-over-year?
Nektar Therapeutics's financing cash flow increased by 7564885.7% year-over-year, from $7K to $529.55M.
What is the long-term trend for Nektar Therapeutics's financing cash flow?
Over 4 years (2021 to 2025), Nektar Therapeutics's financing cash flow has grown at a 49.4% compound annual growth rate (CAGR), from $36.24M to $180.57M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Nektar Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude